Patients' and oncologists' views on the treatment and care of advanced ovarian cancer in the UK: Results from the ADVOCATE study

British Journal of Cancer

Volumn 108, Issue 11, 2013, Pages 2264-2271

  Jenkins, V ^a   Catt, S ^a   Banerjee, S ^b   Gourley, C ^c   Montes, A ^d   Solis Trapala, I ^a   Monson, K ^a   Fallowfield, L ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d GUY S HOSPITAL   (United Kingdom)

Author keywords

Advanced ovarian cancer; Chemotherapy treatments; Maintenance therapy; Oncologists' views; Patients' views; Supportive care

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; HORMONE; PACLITAXEL;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADVANCED CANCER; ALLERGIC REACTION; ANEMIA; ARTHRALGIA; ARTICLE; BLOATING; BLOOD CLOT; BONE PAIN; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL (TOPIC); COMMON COLD; CONSTIPATION; CYTOREDUCTIVE SURGERY; DEHYDRATION; DELAYED DIAGNOSIS; DIARRHEA; DYSPNEA; EMOTIONAL DISORDER; EXPECTATION; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GENERAL PRACTITIONER; HAIR LOSS; HAND FOOT SYNDROME; HEARING IMPAIRMENT; HOT FLUSH; HUMAN; HYSTERECTOMY; INSOMNIA; LAPAROTOMY; LEG PAIN; LOSS OF APPETITE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MEDICAL ONCOLOGIST; MOUTH ULCER; NAUSEA; OVARY CANCER; PAIN; PARESTHESIA; PATIENT ATTITUDE; PATIENT CARE; PERSONAL EXPERIENCE; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; QUALITY OF LIFE; QUESTIONNAIRE; SIDE EFFECT; SMELLING DISORDER; SORE THROAT; STRUCTURED INTERVIEW; SYMPTOM ASSESSMENT; TASTE DISORDER; THROMBOCYTOPENIA; THRUSH; TOOTH DISEASE; UNITED KINGDOM; VOMITING; WEIGHT REDUCTION; CLINICAL PRACTICE; DISEASE FREE SURVIVAL; MIDDLE AGED; ONCOLOGY; OVARY TUMOR; STATISTICS; SURVIVAL RATE;

DISEASE-FREE SURVIVAL; FEMALE; GREAT BRITAIN; HUMANS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; OVARIAN NEOPLASMS; PATIENT ACCEPTANCE OF HEALTH CARE; PHYSICIAN'S PRACTICE PATTERNS; QUALITY OF LIFE; QUESTIONNAIRES; SURVIVAL RATE;

EID: 84884171781     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.223     Document Type: Article

References (22)

1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Takeda F (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5): 365-376.
2. Arraras JI, Greimel E, Sezer O, Chie W-C, Bergenmar M, Costantini A, Young T, Velikova G (2010) An international validation study of the EORTC QLQ-INFO25 questionnaires: an instrument to assess the information given to cancer patients. Eur J Cancer 46: 2726-2738.
3. Basch E, Abernethy AP (2011) Supporting clinical practice decisions with real-time patient-reported outcomes. J Clin Oncol 29: 954-956.
4. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Liang SX (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer (GOG-0218 study. N Engl JMed 365: 2473-2483.
5. Cancer Research UK (2012) Ovarian cancer statistics www.cancerresearchuk.org/cancer-info/cancerstats/types/ovary/ (accessed 2 Nov 2012).
6. Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, Nur U, Tracey E, Coory M, Hatcher J, McGahan CE, Turner D, Marrett L, Gjerstoff ML, Johannesen TB, Adolfsson J, Lambe M, Lawrence G, Meechan D, Morris EJ, Middleton R, Steward J, Richards MA. the ICBP Module 1 Working Group (2011) Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 377: 127-138.
7. Cox A, Bull E, Cockle-Hearne J, Knibb W, Potter C, Faithfull S (2008) Nurse led telephone follow up in ovarian cancer: a psychosocial perspective. Eur J Oncol Nurs 12: 412-417.
8. Cox K, Wilson E, Health L, Collier J, Jones L, Johnston I (2006) Preferences for follow-up after treatment for lung cancer. Cancer Nurs 29: 176-187.
9. Department of Health National Cancer Patient Experience Survey 2011/12 - National Report 17 August 2012 www.dh.gov.uk/publications.
10. Donovan KA, Greene PG, Shuster Jr. JL, Partridge EE, Tucker DC (2002) Treatment preferences in recurrent ovarian cancer. Gynecolog Oncol 86: 200-211.
11. du Bois A, Rochon J, Pfisterer J, Hoskins WJ (2009) Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review. Gynecol Oncol 112(2): 422-436.
12. Elit L, Levine M, Gafni A, Whelan T, Doig G, Streiner D, Rosen B (1996) Patients' preferences for therapy in advanced epithelial ovarian cancer: development, testing, and application of a bedside decision instrument. Gynecol Oncol 62: 329-335.
13. Fallowfield LJ, Fleissig A (2012) The value of progression-free survival to patients with advanced-stage cancer. Nat Rev Clin Oncol 9: 41-47.
14. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A. The EORTC Quality of Life Group (2001) The EORTC QLQC30 Scoring Manual, 3rd Edn. European Organisation for Research and Treatment of Cancer: Brussels.
15. Kristensen G, Perren T, Qian W, Pfisterer J, Ledermann JA, Joly F, Carey MS, Beale PJ, Cervantes A, Oza AM. and GCIG (2011) Results of interim analysis of overall survival in the GCIG ICON7 phase III randomised trial of bevacizumab in women with newly diagnosed ovarian cancer. (Abstract). In: Proceedings of the Annual Meeting of the American Society of Clinical Oncology (ASCO); June 3-7 Chicago, IL, USA.
16. Greimel E, Bottomley A, Cull A, Waldenstrom A-C, Arraras J, Chauvenet L, Holzner B, D'haese S (2003) An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. EJC 39: 1402-1408.
17. Havrilesky LJ, Abernethy AP (2013) Quality of life in ICON7: need for patients' perspectives. Lancet Oncol (2013) 14(3): 183-185.
18. Lutgendorf SK, De Geest K, Bender D, Ahmed A, Goodheart MJ, Dahmoush L, Zimmerman MB, Sood AK (2012) Social influences on clinical outcomes of patients with ovarian cancer. J Clin Oncol 30(23): 2885-2890.
19. Meropol NJ, Egleston BL, Buzaglo JS, Benson III AB, Cegala DJ, Diefenbach MA, Fleisher L, Trinastic J (2008) Cancer patients' preferences for quality and length of life. Cancer 113: 3459-3466.
20. National Institute for Health and Clinical Excellence (2003) Guidance on the use of paclitaxel in the treatment of ovarian cancer. NICE technology appraisal guidance 55. National Institute for Health and Clinical Excellence: London, UK.
21. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Oza AM (2011) A phase 3 trial of bevacizumab in ovarian cancer (ICON7 study). N Engl J Med 365: 2484-2496.
22. Stark D, Nankivell M, Pujade-Lauraine E, Kristensen G, Elit L, Stockler M, Hilpert F, Cervantes A, Brown J, Lanceley A, Velikova G, Sabate E, Pfisterer J, Carey MS, Beale P, Qian W, Swart AM, Oza A, Perren T (2013) Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncol 14(3): 236-243.